Share on StockTwits

Provectus Biopharmaceuticals (NYSE:PVCT) saw a large drop in short interest in August. As of August 15th, there was short interest totalling 1,682,848 shares, a drop of 7.3% from the July 31st total of 1,814,881 shares, American Banking and Market News reports. Based on an average trading volume of 259,296 shares, the short-interest ratio is presently 6.5 days. Currently, 1.0% of the company’s stock are sold short.

Shares of Provectus Biopharmaceuticals (NYSE:PVCT) opened at 0.9875 on Thursday. Provectus Biopharmaceuticals has a 1-year low of $0.30 and a 1-year high of $6.03. The stock has a 50-day moving average of $0.91 and a 200-day moving average of $1.64. The company’s market cap is $174.4 million.

Provectus Biopharmaceuticals Inc, formerly Provectus Pharmaceuticals, Inc, is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications.

Receive News & Ratings for Provectus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.